Most Recent Articles by Deborah Weinstein
Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.
Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.
Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal
The $38-million deal expands the reach of rare-disease campaigns.
More Articles by Deborah Weinstein
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Lawmakers propose allowing pharma companies to share some off-label information
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Apple's ResearchKit: Five Guidelines for Pharma